Skip to main content
SNYR
NASDAQ Life Sciences

Synergy CHC Reports Steep Losses, Increased Cash Burn, and Informal Default Allegation Amid Highly Dilutive Financing

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
9
Price
$0.305
Mkt Cap
$4.435M
52W Low
$0.285
52W High
$4
Market data snapshot near publication time

summarizeSummary

Synergy CHC Corp. reported a significant net loss and increased cash burn in Q1 2026, alongside highly dilutive financing activities and an informal default allegation from a senior lender, raising serious going concern issues.


check_boxKey Events

  • Significant Financial Deterioration

    The company reported a net loss of $2.57 million for Q1 2026, a sharp decline from a net income of $0.88 million in Q1 2025. Revenue decreased by $2.68 million, and cash used in operating activities more than doubled to $2.04 million. Working capital shifted from a surplus to a $0.50 million deficit.

  • Highly Dilutive Equity Financing

    Subsequent to quarter-end in April 2026, the company sold 3,278,030 shares under its ATM program, raising $2.67 million in gross proceeds. This represents approximately 60% of the company's current market capitalization, indicating substantial dilution for existing shareholders. An Equity Line of Credit (ELOC) was also entered into.

  • Lender Warrant Issued on Default Condition

    In March 2026, the company issued 3,000,000 common stock warrants to a lender (ACP Agency, LLC) with a nominal exercise price of $0.00001 per share, exercisable upon a 'Qualified Event of Default' under the credit agreement. This represents a potential 20% dilution based on current outstanding shares.

  • Informal Default Allegation

    ACP Agency, LLC has informally alleged a default under the Credit Agreement, which the company disputes. A formal declaration of default could severely impact the company's liquidity and financial stability.


auto_awesomeAnalysis

Synergy CHC Corp. reported a significant deterioration in its financial health for Q1 2026, with a substantial net loss and increased cash burn from operations. The company's working capital shifted from a surplus to a deficit, highlighting severe liquidity challenges. Despite management's assertion that recent financing activities alleviate going concern doubts, the underlying financials remain dire. The company is relying on highly dilutive equity financing, including a recent $2.67 million ATM program drawdown (representing 60% of its current market cap) and an equity line of credit. A critical $10 million equity raise is mandated by September 2026 to avoid a 2% interest rate step-up on its term loan. Furthermore, a senior lender has informally alleged a default, which the company disputes, adding significant uncertainty to its debt obligations. The issuance of 3 million warrants to a lender at a nominal exercise price, exercisable upon default, underscores the precarious financial position.

At the time of this filing, SNYR was trading at $0.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4M. The 52-week trading range was $0.28 to $4.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed SNYR - Latest Insights

SNYR
May 14, 2026, 8:19 AM EDT
Filing Type: 10-Q
Importance Score:
9
SNYR
May 11, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
SNYR
Apr 17, 2026, 4:16 PM EDT
Filing Type: PRE 14A
Importance Score:
9
SNYR
Apr 01, 2026, 6:15 AM EDT
Source: Wiseek News
Importance Score:
9
SNYR
Mar 31, 2026, 9:23 PM EDT
Filing Type: 10-K
Importance Score:
9
SNYR
Mar 25, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
9
SNYR
Mar 25, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
9
SNYR
Mar 03, 2026, 5:23 PM EST
Source: Wiseek News
Importance Score:
8
SNYR
Mar 03, 2026, 5:20 PM EST
Filing Type: 8-K
Importance Score:
8